RE:Financials and MD&A next weekWhy were the Shadow Lake folks brought in? If I recall, Shadow Lake, once called Willow Tree Capital Group, was
brought in in 2014 because of their evaluative methods for life science drugs, acquisitions and mergers. (Mergers?!!! What!?)
There may not be too many Shadow Lake introductions needed. I suspect that Bioasis may already be in advanced discussions with potential BD partners. Shadow Lake would be very valuable sitting at the table to counsel Bioasis in business agreement negotiations. With their counsel and the Lind financing, Bioasis may no longer have to settle for low-ball deals as we've seen in the pass.
What I wonder is how many negotiations are going on around the preclinical stuff Bioasis is doing, and under the guise of Material Transfer Agreements.
Probably busier than we think. I don't expect much about that stuff in the financials and MD&A although we should learn whether Prothena renewed their option agreement before the July 31 deadline. If so, we might see a little jolt of revenue and confirmation that xB3 is still their huckleberry. However, if their first exclusive target was amyloid beta (Alzheimer's) then they're probably not too happy with Biogen's news today. Total
sales of aducanumab were only $300,000.00. Health insurance industry doesn't want to cover it. Yoiks!
I like xB3-004 for AD. Slow the neuroinflammation, slow the neurodegeneration. And slow the cognitive decline.
jd